NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma.

Sponsor

Chimerix

---

ClinicalTrials.gov Identifier: NCT02863991

Official Title: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

First Posted: August 11, 2016

Click here for details on ClinicalTrials.gov

---

ONC201

Akt/ERK Inhibitor ONC201 (Code C113792)

Akt/ERK Inhibitor ONC201

ONC-201

ONC201

TIC10

---

Drug: ONC201

---

Location

United States, New York

United States, Pennsylvania